Diabetes care Exam: Quiz!

20 Questions | Total Attempts: 235

SettingsSettingsSettings
Diabetes care Exam: Quiz! - Quiz

.


Questions and Answers
  • 1. 
    The United Kingdom Prospective Diabetes Study (UKPDS) showed that intensive therapy (mean A1C value of 7%) with OHAs of insulin resulted in a decreased risk of microvascular complications compared with conventional therapy with diet (mean A1C value of 7.9%) at the end of the study 1997. According to UKPDS 0.9% reduction in A1C at 10 years was associated with a ___ reduction in microvascular endpoints.
    • A. 

      5%

    • B. 

      15%

    • C. 

      25%

    • D. 

      35%

  • 2. 
    According to a meta-analysis of intensive glucose-lowering trials, the benefit of different interventions with 5-year treatment, which of the following results in better reduction of CV events?
    • A. 

      Reduction of systolic BP (4 mmHg)

    • B. 

      Reduction of HbA1C (0.9%)

    • C. 

      Reduction of LDL cholesterol (38.6 mg/dL)

    • D. 

      All of the above

  • 3. 
    In elderly long-standing diabetes with comorbidities the HBA1C goal is
    • A. 

      6-6.5%

    • B. 

      6.5-7%

    • C. 

      7-7.5%

    • D. 

      7.5-8%

  • 4. 
    According to East-West Study:
    • A. 

      Patients with DM but no CHD experience a higher rate of MI as patients without DM but with CHD

    • B. 

      Patients with DM but no CHD experience a lower rate of MI as patients without DM but with CHD

    • C. 

      Patients with DM but no CHD experience a similar rate of MI as patients without DM but with CHD

  • 5. 
    According to ADA guidelines diagnostic criteria for diabetes by HbA1C
    • A. 

      Diabetes is diagnosed if HbA1c ≥ 6% in at least 2 measurements

    • B. 

      Diabetes is diagnosed if HbA1c ≥ 6.5% in at least 2 measurements

    • C. 

      Diabetes is diagnosed if HbA1c ≥ 7% in at least 2 measurements

    • D. 

      Diabetes is diagnosed if HbA1c ≥ 7.5% in at least 2 measurements

  • 6. 
    A 50-year-old man with a history of myocardial infarction has new-onset type 2 diabetes with HbA1C 8%. You are considering drug treatment, the first drug to be considered is
    • A. 

      Metformin

    • B. 

      Gliptins

    • C. 

      SGLT2 inhibitor

    • D. 

      GLP-1 agonists

  • 7. 
    According to ADA all of the following are the criteria for the diagnosis of diabetes except
    • A. 

      FPG ≥ 110 mg/dL

    • B. 

      HbA1C ≥ 6.5%

    • C. 

      2-h PG ≥ 200 mg/dL

    • D. 

      Classical symptoms of hyperglycemia and random PG ≥ 200 mg/dL

  • 8. 
    According to ADA guidelines, the following combination of drugs is not recommended in the treatment of T2D.
    • A. 

      DPP-4 inhibitors and GLP-1 agonists

    • B. 

      GLP-1 agonists and SGLT2 inhibitors

    • C. 

      SGLT2 inhibitors and TZDs

    • D. 

      DPP-4 inhibitors and TZDs

  • 9. 
    The following drugs have shown cardiovascular benefits by decreasing MACE
    • A. 

      Metformin and insulin

    • B. 

      DPP4 inhibitors and Metformin

    • C. 

      SGLT2 inhibitors and GLP-1 agonists

    • D. 

      SGLT2 inhibitors and long acting GLP-1 agonists

  • 10. 
    The following drugs are not to be used in T2D patients with CHF.
    • A. 

      GLP1 agonists and SGLT2i

    • B. 

      α-glucosidase inhibitors and Linagliptin

    • C. 

      Linagliptin and Dapagliflozin

    • D. 

      TZDs and Saxagliptin

  • 11. 
    One of the following drugs has shown benefit in cardiovascular outcomes in CHF in patients with and without T2DM?
    • A. 

      Liraglutide

    • B. 

      Empagliflozin

    • C. 

      Metformin

    • D. 

      Dapagliflozin

  • 12. 
    Hypoglycemia is more common with the following drug/drugs.
    • A. 

      Dapagliflozin

    • B. 

      Linagliptin

    • C. 

      Glimepride

    • D. 

      2&3

    • E. 

      All of the above

  • 13. 
    Which of the following drugs has shown significant cardiovascular benefit in T2D with high CVD risk?
    • A. 

      Empagliflozin

    • B. 

      Dapagliflozin

    • C. 

      Sitagliptin

    • D. 

      Insulin

  • 14. 
    Which of the following drugs can be used in patients with CKD (eGFR < 30ml/min)
    • A. 

      Metformin

    • B. 

      Glibenclamide

    • C. 

      Linagliptin

    • D. 

      Empagliflozin

  • 15. 
    Testing for diabetes in asymptomatic individuals should be considered in overweight or obese who have one or more of the following risk factors except:
    • A. 

      First-degree relative with diabetes

    • B. 

      Hypertension (≥140/90 mmHg or therapy for hypertension)

    • C. 

      Active smoker

    • D. 

      Women with polycystic ovary syndrome

  • 16. 
    Which of the following drug/drugs on long term treatment requires least number of patients to prevent one CV death (NNT) in T2D?
    • A. 

      Statins

    • B. 

      Antihypertensives

    • C. 

      Aspirin

    • D. 

      Empagliflozin

    • E. 

      Liraglutide

  • 17. 
    Fournier’s gangrene (acute perineal necrotizing fasciitis) is a serious complication of drug treatment of T2D. Which drug/drug class has been associated with this complication?
    • A. 

      Saxagliptin

    • B. 

      SGLT2i

    • C. 

      GLP-1 agonists

    • D. 

      Rosiglitazone

  • 18. 
    Multiple gas-containing cysts in the submucosal or subserosal layer of the intestine (Pneumatosis) It may be associated with a range of GI conditions such as bowel gangrene to inflammatory bowel disease and rarely with mechanical ventilation and endoscopic procedures. Which antidiabetic drug is associated with this rare condition?
    • A. 

      Rosiglitazone

    • B. 

      Dapagliflozin

    • C. 

      Saxagliptin

    • D. 

      Acarbose

  • 19. 
    The following class of drugs acts by stimulating the pancreas to produce more insulin.
    • A. 

      Sulfonylureas

    • B. 

      Meglitinides

    • C. 

      Gliptins

    • D. 

      A and b

    • E. 

      A and c

  • 20. 
    The following oral hypoglycemic agent raised serious concern about cardiovascular safety resulting in FDA guidance to industry to evaluate CV risk in new therapies to treat T2D in 2008.
    • A. 

      Saxagliptin

    • B. 

      Rosiglitazone

    • C. 

      Repaglinide

    • D. 

      Exenatide

Back to Top Back to top